The reimbursement listing of the advanced ADC anti-cancer drug Enhertu is imminent. The company completed drug pricing negotiations with the National Health Insurance Service at a ‘superfast’ speed when considering the slow progress it had made during previous procedures. At this pace, Enhertu is likely to be reimbursed in April this year.

After passing HITA’s Cancer Disease Deliberation Committee last year, Enhertu’s reimbursement agenda was rejected by the Drug Reimbursement Evaluation Committee 8 times and was unable to cross the threshold until February this year. But its pricing negotiation took less than one month. This is both encouraging and unusual.

Adding on to the wonder, t